Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Genetic risk scores associated with baseline lipoprotein subfraction concentrations do not associate with their responses to fenofibrate.

Frazier-Wood AC, Wojczynski MK, Borecki IB, Hopkins PN, Lai CQ, Ordovas JM, Straka RJ, Tsai MY, Tiwari HK, Arnett DK.

Biology (Basel). 2014 Aug 25;3(3):536-50. doi: 10.3390/biology3030536.

2.

The potential applications of Apolipoprotein E in personalized medicine.

Villeneuve S, Brisson D, Marchant NL, Gaudet D.

Front Aging Neurosci. 2014 Jul 8;6:154. doi: 10.3389/fnagi.2014.00154. eCollection 2014. Review.

3.

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB.

Diabetes Care. 2014;37(3):686-93. doi: 10.2337/dc13-0790. Epub 2013 Dec 2.

4.

PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

Contreras AV, Torres N, Tovar AR.

Adv Nutr. 2013 Jul 1;4(4):439-52. doi: 10.3945/an.113.003798. Review.

5.

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.

Aslibekyan S, Goodarzi MO, Frazier-Wood AC, Yan X, Irvin MR, Kim E, Tiwari HK, Guo X, Straka RJ, Taylor KD, Tsai MY, Hopkins PN, Korenman SG, Borecki IB, Chen YD, Ordovas JM, Rotter JI, Arnett DK.

PLoS One. 2012;7(10):e48663. doi: 10.1371/journal.pone.0048663. Epub 2012 Oct 31.

6.

Exome sequencing identifies 2 rare variants for low high-density lipoprotein cholesterol in an extended family.

Reddy MV, Iatan I, Weissglas-Volkov D, Nikkola E, Haas BE, Juvonen M, Ruel I, Sinsheimer JS, Genest J, Pajukanta P.

Circ Cardiovasc Genet. 2012 Oct 1;5(5):538-46. doi: 10.1161/CIRCGENETICS.112.963264. Epub 2012 Aug 25. Erratum in: Circ Cardiovasc Genet. 2012 Dec;5(6):e60. Ruel, Miina Juvonen Isabelle [corrected to Juvonen, Miina]; Ruel, Miina Juvonen Isabelle [corrected to Ruel, Isabelle].

7.

The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.

Frazier-Wood AC, Ordovas JM, Straka RJ, Hixson JE, Borecki IB, Tiwari HK, Arnett DK.

Pharmacogenomics J. 2013 Aug;13(4):312-7. doi: 10.1038/tpj.2012.9. Epub 2012 May 1.

8.

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.

Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Shen J, Lai CQ, Ordovas JM, Arnett DK.

Pharmacogenet Genomics. 2012 Mar;22(3):191-7. doi: 10.1097/FPC.0b013e32834fdd41.

9.

Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.

Feitosa MF, An P, Ordovas JM, Ketkar S, Hopkins PN, Straka RJ, Arnett DK, Borecki IB.

Atherosclerosis. 2011 Apr;215(2):435-9. doi: 10.1016/j.atherosclerosis.2011.01.011. Epub 2011 Jan 21.

10.

Peroxisome proliferator-activated receptor alpha target genes.

Rakhshandehroo M, Knoch B, Müller M, Kersten S.

PPAR Res. 2010;2010. pii: 612089. doi: 10.1155/2010/612089. Epub 2010 Sep 26.

11.

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Irvin MR, Kabagambe EK, Tiwari HK, Parnell LD, Straka RJ, Tsai M, Ordovas JM, Arnett DK.

Circ Cardiovasc Genet. 2010 Oct;3(5):462-7. doi: 10.1161/CIRCGENETICS.110.950667. Epub 2010 Aug 21.

12.

Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels.

Paglialunga S, Julien P, Tahiri Y, Cadelis F, Bergeron J, Gaudet D, Cianflone K.

J Lipid Res. 2009 Jun;50(6):1109-19. doi: 10.1194/jlr.M800430-JLR200. Epub 2009 Feb 23.

13.

Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.

Shen J, Ordovas JM.

Clin Chem. 2009 Feb;55(2):256-64. doi: 10.1373/clinchem.2008.117754. Epub 2008 Dec 12. Review.

14.

Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.

Perez-Martinez P, Corella D, Shen J, Arnett DK, Yiannakouris N, Tai ES, Orho-Melander M, Tucker KL, Tsai M, Straka RJ, Province M, Kai CS, Perez-Jimenez F, Lai CQ, Lopez-Miranda J, Guillen M, Parnell LD, Borecki I, Kathiresan S, Ordovas JM.

Am J Clin Nutr. 2009 Jan;89(1):391-9. doi: 10.3945/ajcn.2008.26363. Epub 2008 Dec 3.

15.

Gene-environment interactions and susceptibility to metabolic syndrome and other chronic diseases.

Ordovas JM, Shen J.

J Periodontol. 2008 Aug;79(8 Suppl):1508-13. doi: 10.1902/jop.2008.080232. Review.

16.

Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.

Shen J, Arnett DK, Parnell LD, Peacock JM, Lai CQ, Hixson JE, Tsai MY, Province MA, Straka RJ, Ordovas JM.

Diabetes Care. 2008 May;31(5):910-5. doi: 10.2337/dc07-1687. Epub 2008 Feb 19.

17.

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SL.

Eur J Hum Genet. 2008 May;16(5):603-13. doi: 10.1038/sj.ejhg.5202003. Epub 2008 Jan 23.

18.
19.
20.

Pharmacogenetics of lipid diseases.

Ordovas JM.

Hum Genomics. 2004 Jan;1(2):111-25. Review.

Items per page

Supplemental Content

Write to the Help Desk